HOME >> BIOLOGY >> NEWS
Sitagliptin, a new investigational treatment for type 2 diabetes, may offer new hope for patients

There are currently more than 194 million people with diabetes worldwide and this figure could exceed 333 million by 2025 if untreated. [2] Current treatments for type 2 diabetes are often limited by their side effect profile, route of administration or difficulties in sustaining glucose control. [3] As a result, there is a need for better tolerated treatments that do not cause weight gain and produce less risk of hypoglycaemia for patients with type 2 diabetes. The results of the two Phase II studies indicate that sitagliptin, an investigational diabetes drug, appears to control blood sugar with a low incidence of hypoglycaemia and with a neutral effect on body weight.

In the Phase II studies of more than 1,000 patients, ''sitagliptin'', Merck Sharp & Dohme's investigational medicine from a new class of diabetes treatments called dipeptidyl peptidase 4 (DPP-4) inhibitors, improved glycaemic control in patients with type 2 diabetes and exhibited a safety and tolerability profile similar to placebo. In addition, patients taking sitagliptin experienced no significant weight gain and a low risk of hypoglycaemia.

"Results from the studies conducted to date are very promising," said Peter Stein, Senior Director in Clinical Research, Metabolism, Merck Research Laboratories, Rahway, NJ, USA. "The need for well tolerated therapies which achieve better glycaemic control than current therapies is well known and we are confident that these short-term clinical studies demonstrate proof of concept for sitagliptin, offering a new hope for type 2 diabetes patients. Ongoing Phase III trials should provide greater insight into the efficacy and tolerability profile of sitagliptin over a longer period of time".

Study 1: Effect of sitagliptin oral tablets on glycaemic control
Results from a 12-week, double-blind, placebo-controlled, parallel group study in patients with type 2 diabetes showed that sitagliptin oral tablets significantly r
'"/>

Contact: Catherine Pannell
cpannell@hillandknowlton.com
44-207-413-3059
Merck & Co., Inc.
14-Sep-2005


Page: 1 2 3

Related biology news :

1. FUZEON with investigational HIV drug results in remarkable number of patients achieving undetectable
2. Providence health system shows investigational osteoporosis therapy increases bone mineral density
3. Amgen investigational therapy, AMG 162, increased bone mineral density with twice yearly injection
4. New system of wastewater treatment could reduce the size of treatment plants by half
5. UCF research links proteins, stem cells and potential Alzheimers treatment
6. Geisinger scientist seeks cure for Lou Gehrigs disease, creating device to find treatment
7. System to analyze beating heart stem cells could lead to heart attack treatments
8. Gene expression pattern could lead to improved treatment of pediatric septic shock
9. Molecular detectors may refine cancer treatment
10. First genome-wide study of infectious disease opens new avenues for HIV treatment, vaccines
11. A new method of adult stem cell growth efficacious in treatment of disorders of the cornea

Post Your Comments:
(Date:8/29/2014)... modern materials that are light, flexible and highly conductive ... electronic paper. , Making such concepts affordable enough for ... of working with copper nanowires and a PVA "nano ... in the field of ultra-lightweight "aerogel monoliths" has largely ... nanowires. , By turning instead to copper, both ...
(Date:8/28/2014)... America (ESA) is pleased to announce the selection of ... Society. Honorary Membership acknowledges those who have served ESA ... the affairs of the Society that has reached an ... the ESA Governing Board and then voted on by ... the Awards Ceremony at Entomology 2014, ESA,s Annual Meeting ...
(Date:8/28/2014)... in German . ... name to a striking pattern of blue stripes alternating with ... silvery cells, and yellow cells emerge during growth in the ... multilayered mosaic to compose the characteristic colour pattern. ... to interact to form proper stripes, the embryonic origin of ...
Breaking Biology News(10 mins):Copper shines as flexible conductor 2Fred Baxendale selected as Honorary Member of the Entomological Society of America 2How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3
(Date:8/28/2014)... (PRWEB) August 28, 2014 PrimeSource ... construction materials, selected SoundConnect to support ... cloud based audio and web conferencing platform GlobalMeet ... support PrimeSource’s employees’ needs. SoundConnect delivers award ... , PrimeSource Building Products will be utilizing ...
(Date:8/28/2014)... August 28, 2014 Whitehouse Laboratories is ... term partnership with PTI Inspection Systems that ... state of the art leak testing method development and ... instruments currently available. As part of this agreement, Whitehouse ... Voltage Leak Detection Instrument developed and manufactured by ...
(Date:8/27/2014)... Austin, TX (PRWEB) August 27, 2014 ... $6 million in Series B funding and secured Otter ... and investment capital will accelerate commercialization of GGI’s Agriplier™ ... multiple crop types. , “Since our first meeting, ... commitment to the biological product space,” said Alan Sobba, ...
(Date:8/27/2014)... 2014 In 2013, Lawrence ... Livermore National Security LLC (LLNS), was awarded ... a state-of-the-art laser system for the European Union's ... construction in the Czech Republic. , When commissioned ... called the " High repetition-rate Advanced Petawatt Laser ...
Breaking Biology Technology:PrimeSource Chooses SoundConnect as Collaboration Provider 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3
Cached News: